Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancer

Abstract Background We examined real-world outcomes of patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with apalutamide plus androgen deprivation therapy (ADT). The current study, reflecting real-life practice, included specific subpopulations not evaluated in the pivotal...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Martin Boegemann, Mostefa Bennamoun, Louis Marie Dourthe, Juan Antonio Encarnacion, Axel Hegele, Eva Hellmis, Igor Latorzeff, Wolfgang Leicht, Julián Oñate-Celdrán, Antonio Rosino-Sánchez, Krystelle Hanna, Joana Lencart, Martin Lukac, Claudio A. Schioppa, Suzy Van Sanden, Gero Kramer
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMC 2025-07-01
סדרה:	BMC Cancer
נושאים:	Apalutamide Metastatic hormone-sensitive prostate cancer Prostate-specific antigen
גישה מקוונת:	https://doi.org/10.1186/s12885-025-14294-7
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!